-
FDA aims to evaluate regulatory pathways, safety of CBD, cannabis products
The FDA has set a public hearing for May 31 on the safety of cannabis products. -
Sharpless named acting FDA commissioner
Norman Sharpless, currently the head of the National Cancer Institute, will serve as acting FDA commissioner when Scott Gottlieb steps down next month.